Low dose of GRP78- Targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo

Oncology Reports

Volumn 35, Issue 6, 2016, Pages 3151-3158

  Gabrysiak, Magdalena ^a   Wachowska, Malgorzata ^a   Barankiewicz, Joanna ^a,b,c   Pilch, Zofia ^a   Ratajska, Anna ^a   Skrzypek, Ewa ^a   Winiarska, Magdalena ^a   Domagala, Antoni ^a   Rygiel, Tomasz P ^a   Jozkowicz, Alicja ^d   Boon, Louis ^e   Golab, Jakub ^a   Firczuk, Malgorzata ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^c INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e EPIRUS Biopharmaceuticals Netherlands BV   (Netherlands)

Author keywords

Cancer; EGF subA; Immune response; Photodynamic therapy; T cell

Indexed keywords

CYTOTOXIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE REGULATED PROTEIN 78; PHOTOFRIN; REACTIVE OXYGEN METABOLITE; SUBTILASE CYTOTOXIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ESCHERICHIA COLI PROTEIN; HEAT SHOCK PROTEIN; HYBRID PROTEIN; MOLECULAR CHAPERONE GRP78; PHOTOFRIN II; PHOTOSENSITIZING AGENT; SUBTILASE CYTOTOXIN, E COLI; SUBTILISIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL PROTECTION; CELL SELECTION; CELL VIABILITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENDOPLASMIC RETICULUM; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOREGULATION; IN VIVO STUDY; LETHAL DOSE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN TARGETING; T CELL DEPLETION; T LYMPHOCYTE; TUMOR ABLATION; TUMOR GROWTH; TUMOR VASCULARIZATION; UNFOLDED PROTEIN RESPONSE; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; LIVER; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOTOCHEMOTHERAPY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DIHEMATOPORPHYRIN ETHER; EPIDERMAL GROWTH FACTOR; ESCHERICHIA COLI PROTEINS; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; LIVER; MICE; MICE, INBRED BALB C; MICE, SCID; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RECOMBINANT FUSION PROTEINS; SUBTILISINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964881583     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4723     Document Type: Article

References (25)

1. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al: Photodynamic therapy of cancer: An update. CA Cancer J Clin 61: 250-281, 2011.
2. Firczuk M, Nowis D and Gołab J: PDT-induced inflammatory and host responses. Photochem Photobiol Sci 10: 653-663, 2011.
3. Korbelik M, Krosl G, Krosl J and Dougherty GJ: The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res 56: 5647-5652, 1996.
4. Korbelik M and Cecic I: Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 137: 91-98, 1999.
5. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al: A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 31: 1062-1079, 2012.
6. Korbelik M, Sun J and Cecic I: Photodynamic therapy-induced cell surface expression and release of heat shock proteins: Relevance for tumor response. Cancer Res 65: 1018-1026, 2005.
7. Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT and Morgan J: Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 64: 2120-2126, 2004.
8. Kabingu E, Oseroff AR, Wilding GE and Gollnick SO: Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res 15: 4460-4466, 2009.
9. Korbelik M and Cecic I: Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. J Photochem Photobiol B 44: 151-158, 1998.
10. Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, Boon L, Mroz P, Hamblin MR and Golab J: 5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur J Cancer 50: 1370-1381, 2014.
11. Jalili A, Makowski M, Switaj T, Nowis D, Wilczynski GM, Wilczek E, Chorazy-Massalska M, Radzikowska A, Maslinski W, Biały L, et al: Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res 10: 4498-4508, 2004.
12. Xue LY, Agarwal ML and Varnes ME: Elevation of GRP-78 and loss of HSP-70 following photodynamic treatment of V79 cells: Sensitization by nigericin. Photochem Photobiol 62: 135-143, 1995.
13. Luo B and Lee AS: The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 32: 805-818, 2013.
14. Paton AW, Beddoe T, Thorpe CM, Whisstock JC, Wilce MC, Rossjohn J, Talbot UM and Paton JC: AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature 443: 548-552, 2006.
15. Paton AW, Srimanote P, Talbot UM, Wang H and Paton JC: A new family of potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med 200: 35-46, 2004.
16. Wang H, Paton JC and Paton AW: Pathologic changes in mice induced by subtilase cytotoxin, a potent new Escherichia coli AB5 toxin that targets the endoplasmic reticulum. J Infect Dis 196: 1093-1101, 2007.
17. Harama D, Koyama K, Mukai M, Shimokawa N, Miyata M, Nakamura Y, Ohnuma Y, Ogawa H, Matsuoka S, Paton AW, et al: A subcytotoxic dose of subtilase cytotoxin prevents lipopolysaccharide- induced inflammatory responses, depending on its capacity to induce the unfolded protein response. J Immunol 183: 1368-1374, 2009.
18. Backer JM, Krivoshein AV, Hamby CV, Pizzonia J, Gilbert K S, Ray YS, Brand H, Paton AW, Paton JC and Backer MV: Chaperone- Targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells. Neoplasia 11: 1165-1173, 2009.
19. Firczuk M, Gabrysiak M, Barankiewicz J, Domagala A, Nowis D, Kujawa M, Jankowska-Steifer E, Wachowska M, Glodkowska-Mrowka E, Korsak B, et al: GRP78- Targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death Dis 4: E741, 2013.
20. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, et al: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: E313, 2005.
21. Makowski M, Grzela T, Niderla J, ŁAzarczyk M, Mróz P, Kopeé M, Legat M, Strusinska K, Koziak K, Nowis D, et al: Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin Cancer Res 9: 5417-5422, 2003.
22. Szokalska A, Makowski M, Nowis D, Wilczynski GM, Kujawa M, Wójcik C, Mlynarczuk-Bialy I, Salwa P, Bil J, Janowska S, et al: Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. Cancer Res 69: 4235-4243, 2009.
23. Korbelik M: Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 14: 329-334, 1996.
24. Kabingu E, Vaughan L, Owczarczak B, Ramsey KD and Gollnick SO: CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer 96: 1839-1848, 2007.
25. Castano AP, Mroz P, Wu MX and Hamblin MR: Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci USA 105: 5495-5500, 2008.